CSL (OTCMKTS:CSLLY) is a global specialty biotechnology company that develops and delivers a range of innovative biotherapies and influenza vaccines. The company’s main business segments are CSL Behring and Seqirus. CSL Behring focuses on plasma-derived and recombinant therapies for people with rare and serious diseases, including bleeding disorders, immune deficiencies, respiratory disorders and hereditary angioedema. Seqirus is one of the world’s largest influenza vaccine providers, offering both egg-based and cell-based vaccines as well as adjuvanted formulations to support seasonal, pre-pandemic and pandemic preparedness.
Founded in 1916 as Commonwealth Serum Laboratories in Australia, CSL has evolved over more than a century into a leading biotech organization. The company was privatized in 1994 and has expanded its global footprint through strategic acquisitions and partnerships. In 2015, CSL acquired Novartis’ influenza vaccine business, now known as Seqirus, enhancing its capabilities in vaccine research, development and manufacturing. CSL maintains extensive plasma collection networks and operates manufacturing facilities across Australia, the United States, Europe and Asia, ensuring a reliable supply of critical therapies and vaccines to patients worldwide.
CSL’s product portfolio includes immunoglobulins, albumin, clotting factors, and specialty proteins for rare diseases, alongside seasonal, cell-based and adjuvanted influenza vaccines. The company invests heavily in research and development, with a pipeline that targets next-generation therapies for autoimmune, cardiovascular and respiratory conditions. CSL also places a strong emphasis on sustainability, ethical sourcing of plasma and adherence to rigorous quality standards throughout its operations.
Under the leadership of President and Chief Executive Officer Paul Perreault, CSL continues to pursue growth through innovation, geographic expansion and strategic collaborations. The company’s executive team brings extensive experience in biotechnology, pharmaceuticals and global supply chain management. CSL’s commitment to addressing unmet medical needs and preparedness for infectious disease threats positions it as a key player in the life sciences industry.
AI Generated. May Contain Errors.
